CN105232865A - 一种精神疾病患者用的护理型中药组合 - Google Patents
一种精神疾病患者用的护理型中药组合 Download PDFInfo
- Publication number
- CN105232865A CN105232865A CN201510791496.3A CN201510791496A CN105232865A CN 105232865 A CN105232865 A CN 105232865A CN 201510791496 A CN201510791496 A CN 201510791496A CN 105232865 A CN105232865 A CN 105232865A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- chinese medicine
- flos
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 230000000474 nursing effect Effects 0.000 title claims abstract description 11
- 230000003340 mental effect Effects 0.000 title abstract 3
- 235000000126 Styrax benzoin Nutrition 0.000 claims abstract description 11
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims abstract description 10
- 239000004870 Styrax Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- 244000028419 Styrax benzoin Species 0.000 claims abstract 4
- 241000628997 Flos Species 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 16
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 8
- 241000217407 Margaritifera Species 0.000 claims description 8
- 241000522620 Scorpio Species 0.000 claims description 8
- 210000003038 endothelium Anatomy 0.000 claims description 8
- 239000009490 scorpio Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 31
- 238000002156 mixing Methods 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract description 3
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000205574 Acorus calamus Species 0.000 abstract 1
- 235000006480 Acorus calamus Nutrition 0.000 abstract 1
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241000722948 Apocynum cannabinum Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241001625026 Cordyceps cicadae Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 244000118681 Iresine herbstii Species 0.000 abstract 1
- 244000183278 Nephelium litchi Species 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 235000004789 Rosa xanthina Nutrition 0.000 abstract 1
- 241000109329 Rosa xanthina Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 235000008411 Sumatra benzointree Nutrition 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 241000157373 Uncaria rhynchophylla Species 0.000 abstract 1
- 244000126014 Valeriana officinalis Species 0.000 abstract 1
- 235000013832 Valeriana officinalis Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229960002130 benzoin Drugs 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 235000019382 gum benzoic Nutrition 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 235000016788 valerian Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 41
- 208000002193 Pain Diseases 0.000 description 31
- 230000036407 pain Effects 0.000 description 30
- 230000001914 calming effect Effects 0.000 description 22
- 230000001276 controlling effect Effects 0.000 description 19
- 206010010904 Convulsion Diseases 0.000 description 18
- 230000036461 convulsion Effects 0.000 description 18
- 206010062717 Increased upper airway secretion Diseases 0.000 description 15
- 208000026435 phlegm Diseases 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 239000000341 volatile oil Substances 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 241000736148 Styrax Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 206010042772 syncope Diseases 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 244000293323 Cosmos caudatus Species 0.000 description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 description 4
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003866 digestant Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OKBGEROEGQDLFK-UHFFFAOYSA-N 3-(2-hydroxypropan-2-yl)-6-methylspiro[4.5]dec-9-ene-10-carbaldehyde Chemical compound CC1CCC=C(C=O)C11CC(C(C)(C)O)CC1 OKBGEROEGQDLFK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940026189 antimony potassium tartrate Drugs 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- UETZJEZFLKASPR-UZWIWUQPSA-N kobusone Chemical compound O=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 UETZJEZFLKASPR-UZWIWUQPSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LSDULPZJLTZEFD-UHFFFAOYSA-N lupulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)(CC=C(C)C)C1=O LSDULPZJLTZEFD-UHFFFAOYSA-N 0.000 description 2
- MGYBYJXAXUBTQF-FSFUDZCRSA-N luteolin 7-O-rutinoside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)c(O)c5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O MGYBYJXAXUBTQF-FSFUDZCRSA-N 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- DVGGLGXQSFURLP-VWMSDXGPSA-N tribuloside Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1)O)O)OC(=O)\C=C\C1=CC=C(O)C=C1 DVGGLGXQSFURLP-VWMSDXGPSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NMLUOJBSAYAYEM-UHFFFAOYSA-N (-)-corynantheidine Natural products C1=CC=C2C(CCN3CC(C(CC33)C(=COC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-UHFFFAOYSA-N 0.000 description 1
- IMNKABOILQOFDL-UHFFFAOYSA-N (-Muscopyridine Natural products C1C(C)CCCCCCCCC2=CC=CC1=N2 IMNKABOILQOFDL-UHFFFAOYSA-N 0.000 description 1
- IMNKABOILQOFDL-CQSZACIVSA-N (10r)-10-methyl-16-azabicyclo[10.3.1]hexadeca-1(16),12,14-triene Chemical compound C1[C@H](C)CCCCCCCCC2=CC=CC1=N2 IMNKABOILQOFDL-CQSZACIVSA-N 0.000 description 1
- WHUDNFJAKJGKBT-LOIXOFCESA-N (3r)-3-(2-hydroxypropan-2-yl)-6-methylspiro[4.5]dec-9-ene-10-carboxylic acid Chemical group CC1CCC=C(C(O)=O)C11C[C@H](C(C)(C)O)CC1 WHUDNFJAKJGKBT-LOIXOFCESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- QRDZSRWEULKVNW-UHFFFAOYSA-N 6-hydroxy-2-oxo-1h-quinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC(=O)NC2=C1 QRDZSRWEULKVNW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- ICWHTQRTTHCUHW-NFAWXSAZSA-N Agarospirol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-NFAWXSAZSA-N 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- WHUDNFJAKJGKBT-UHFFFAOYSA-N Baimuxinic acid Natural products CC1CCC=C(C(O)=O)C11CC(C(C)(C)O)CC1 WHUDNFJAKJGKBT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- NMLUOJBSAYAYEM-GZRFBZBPSA-N Dihydro-corynantheine Natural products CC[C@H]1CN2CCc3c([nH]c4ccccc34)[C@H]2C[C@@H]1C(=COC)C(=O)OC NMLUOJBSAYAYEM-GZRFBZBPSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 108010023832 Florigen Proteins 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- RTMJLHTXLVZSHA-UHFFFAOYSA-N Hirsutine Natural products COC(=O)C12CCCC=C1CN3CCc4cc(O)c(OC)cc4C23 RTMJLHTXLVZSHA-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- BJIOGJUNALELMI-ONEGZZNKSA-N Isoeugenol Natural products COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 1
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 1
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 239000005588 Oxadiazon Substances 0.000 description 1
- CHNUNORXWHYHNE-UHFFFAOYSA-N Oxadiazon Chemical compound C1=C(Cl)C(OC(C)C)=CC(N2C(OC(=N2)C(C)(C)C)=O)=C1Cl CHNUNORXWHYHNE-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- ZKEKDTIKFVCKMW-UHFFFAOYSA-N Trifolin Natural products OCC1OC(Oc2cc(O)ccc2C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O ZKEKDTIKFVCKMW-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- LBRPLJCNRZUXLS-AZVRXDBZSA-N Vincosamide Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](C[C@@H]2C3=C(C4=CC=CC=C4N3)CCN2C2=O)C2=CO1 LBRPLJCNRZUXLS-AZVRXDBZSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- ZLQADKTVJQXDIG-UHFFFAOYSA-N alpha-Agarofuran Natural products C1CC(C2)C(C)(C)OC22C(C)=CCCC21C ZLQADKTVJQXDIG-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001440 androstane derivatives Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- OKBGEROEGQDLFK-JMSVASOKSA-N baimuxinal Natural products C[C@@H]1CCC=C(C=O)[C@]12CC[C@H](C2)C(C)(C)O OKBGEROEGQDLFK-JMSVASOKSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- XWTXUKLVEPDOQT-UHFFFAOYSA-N beta-Agarofuran Natural products C1CC2(C)CCCC(=C)C22OC(C)(C)C1C2 XWTXUKLVEPDOQT-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- BJIOGJUNALELMI-ARJAWSKDSA-N cis-isoeugenol Chemical compound COC1=CC(\C=C/C)=CC=C1O BJIOGJUNALELMI-ARJAWSKDSA-N 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 108010006161 conchiolin Proteins 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000001261 florigenic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- FXHGMKSSBGDXIY-UHFFFAOYSA-N heptanal Chemical compound CCCCCCC=O FXHGMKSSBGDXIY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- NMLUOJBSAYAYEM-AZQGJTAVSA-N hirsutine Chemical compound C1=CC=C2C(CCN3C[C@@H]([C@H](C[C@@H]33)\C(=C/OC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-AZQGJTAVSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 201000008659 immature cataract Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- JPUKWEQWGBDDQB-DTGCRPNFSA-N kaempferol 3-O-beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-DTGCRPNFSA-N 0.000 description 1
- NETQOOYQUZAJCL-UHFFFAOYSA-N kobusone Natural products CC1(C)CC2C1CCC3(C)OC3CC2=O NETQOOYQUZAJCL-UHFFFAOYSA-N 0.000 description 1
- UETZJEZFLKASPR-UHFFFAOYSA-N kobustone Natural products O=C1CCC2OC2(C)CCC2C(C)(C)CC21 UETZJEZFLKASPR-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- VGTGOILROCHQGS-UHFFFAOYSA-N strictosidine lactam Natural products NC(CCC(=O)O)C(=O)OC1OC=C2C(CC3N(CCc4c3[nH]c5ccccc45)C2=O)C1C=C VGTGOILROCHQGS-UHFFFAOYSA-N 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- BJIOGJUNALELMI-UHFFFAOYSA-N trans-isoeugenol Natural products COC1=CC(C=CC)=CC=C1O BJIOGJUNALELMI-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- ZLQADKTVJQXDIG-NWANDNLSSA-N α-agarofuran Chemical compound C1C[C@@H](C2)C(C)(C)O[C@@]22C(C)=CCC[C@@]21C ZLQADKTVJQXDIG-NWANDNLSSA-N 0.000 description 1
- IEZDOTGOEOFYHV-AODWJNRKSA-N β-agarofuran Chemical compound C1CC2(C)CCC=C[C@]22OC(C)(C)[C@H]1C2 IEZDOTGOEOFYHV-AODWJNRKSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药应用领域,特别公开了一种精神疾病患者用的护理型中药组合。该一种精神疾病患者用的护理型中药组合,以安息香,石菖蒲,苏合香,冰片,麝香,蝉花,珍珠母,蒺藜,明党参,紫贝齿,石决明,罗布麻叶,全蝎,牛黄,钩藤,首乌藤,缬草,藏菖蒲,鸡内金,啤酒花,梅花,香附,沉香,玫瑰花和荔枝核为原料,按照一定的重量配比混合制成。本发明配制简单,吸收效果好,药效持续时间长,疗效显著,无副作用,安全性高,生产成本低,有利于病患及时减轻病状。
Description
(一)技术领域
本发明涉及中药应用领域,特别涉及一种精神疾病患者用的护理型中药组合。
(二)背景技术
现代人竞争激烈,由于长时间在各种复杂的社会环境、心里因素及工作各方面的压力而引起的人体内脏功能失调,导致失眠多梦、多疑焦虑、忧郁症、思劳过度、精神恍惚、幻觉妄想、兴奋躁动、哭笑无常、语言错乱、性格孤僻、情绪反常、受惊吓等精神方面的疾病。多数患者脉象弦滑、滑数、细弱或沉弱无力,本病多因思虑过度,而导致肝气郁结,脾气不生,气郁痰结,郁久化热,扰及心神,损及心脾。治疗上述疾病目前采用的方法一是用压制的方法治疗,均以镇定、安眠药物为主,其不能根除疾病,副作用大;二是用和解法治疗,有精神治疗法,手术治疗法,针灸治疗法,也有用中西医结合药物治疗,但上述方法均是治疗时间长,治愈率低,且治疗费用高,疗效不理想;给患者的身心带来极大的伤害,也大大影响了患者正常生活,给人们带来极大的不便。
(三)发明内容
本发明为了弥补现有技术的不足,提供了一种制备简单、疗效显著的一种精神疾病患者用的护理型中药组合。
本发明是通过如下技术方案实现的:
一种精神疾病患者用的护理型中药组合,由以下重量份数的原料制成:
安息香0.6~1.5克,石菖蒲,3~6克,苏合香0.3~1克,冰片0.03~0.1克,麝香0.03~0.1克,蝉花3~6克,珍珠母10~25克,蒺藜6~9克,明党参3~9克,紫贝齿10~15克,石决明3~15克,罗布麻叶6~12克,全蝎2.5~4.5克,牛黄0.15~0.35克,钩藤3~12克,首乌藤9~15克,缬草3~6克,藏菖蒲3~6克,鸡内金3~9克,啤酒花1.5~5克,梅花2.5~4.5克,香附6~9克,沉香1.5~4.5克,玫瑰花3~6克,荔枝核4.5~9克。
其优选的各原料的重量配比为:
安息香0.6克,石菖蒲,3克,苏合香0.3克,冰片0.03克,麝香0.03克,蝉花3克,珍珠母10克,蒺藜6克,明党参3克,紫贝齿10克,石决明3,罗布麻叶6~克,全蝎2.5克,牛黄0.15克,钩藤3克,首乌藤9克,缬草3克,藏菖蒲3克,鸡内金3克,啤酒花1.5克,梅花2.5克,香附6克,沉香1.5克,玫瑰花3克,荔枝核4.5克。
本发明所述中药为散剂或丸剂,将各种原料清洗干净后,打粉混合,制成散剂或丸剂,定量服用。
各原料的药用性能如下所示:
安息香:性平,味辛、苦。归心经、脾经。开窍清神、行气、活血、止痛。属开窍药。用治中风痰厥、气郁暴厥、中恶昏迷、心腹疼痛、产后血晕、小儿惊风。
石菖蒲:性微温,味辛、苦。归心经、胃经。开窍、豁痰、理气、活血、散风、去湿。属开窍药。用治癫痫、痰厥、热病神昏、健忘、气闭耳聋、心胸烦闷、胃痛、腹痛、风寒湿痹、痈疽肿毒、跌打损伤等。石菖蒲、生姜共捣汁灌下,用治痰迷心窍。
苏合香:性温,味辛。归心经、脾经。开窍、辟秽、止痛。属开窍药。用治中风痰厥、猝然昏倒、胸腹冷痛、惊痫。苏合香有抗血栓、抗血小板聚集、抗心肌梗死、扩张冠脉、抗缺氧、抗心律失常、提高冠脉流量作用。此外,还具有祛痰抗炎作用。临床用治冠心病心绞痛、各种疼痛止痛、冻疮、胆道蛔虫病等症。
冰片:性寒,味辛、苦。归心经、脾经、肺经。开窍醒神、清热止痛。属开窍药。用治热闭神昏、痰热内闭、暑热卒厥、小儿惊风及各种疮痈肿痛、溃后不敛、烫火伤、咽喉肿痛、喉痹、目赤肿痛、口舌生疮等。
麝香:性温,味辛。归心经、脾经。开窍醒神、活血通经、消肿止痛。属开窍药。用治热病神昏、中风痰厥、气郁暴厥、中恶昏迷、经闭、癥瘕、难产死胎、心腹暴痛、痈肿瘰疬、咽喉肿痛、跌扑损伤、痹痛麻木。含麝香酮,并含麝吡啶、11种雄甾烷衍生物,尚含胆甾醇类、脂肪、蛋白质、蜡及无机盐。实验表明,本品有兴奋中枢神经和苏醒作用,可兴奋呼吸、加速心搏、升高血压;能增加肾上腺素对β-受体的作用,并有对β-儿茶酚胺的增加作用;对大鼠、家兔、豚鼠的妊娠离体子宫均呈明显兴奋作用,而对非妊娠离体子宫多呈抑制作用;此外,还有强心、抗炎及抑制血管通透性等作用。
蝉花:性寒,味甘。归肝经。清热祛风、镇惊明目、退翳透疹。属平肝息风药下属分类的平抑肝阳药。用治小儿惊风、目赤肿痛、麻疹不透、惊痫、夜啼、心悸等。
珍珠母:性寒,味咸。归肝经、心经。平肝潜阳、定惊明目。属平肝息风药下属分类的平抑肝阳药。用治头痛眩晕、烦躁失眠、肝热目赤、肝虚目昏。主含碳酸钙92%以上,内层角壳蛋白水解后得甘氨酸、丙氨酸和亮氨酸等17种氨基酸。尚含铝、铜、铁、镁等多种无机元素。实验表明,其珍珠层粉具有抗溃疡作用,能显著促进大鼠醋酸性胃溃疡的愈合。珍珠层粉水解物能显著延迟实验大鼠白内障的形成,对初期白内障亦有明显疗效。珍珠层粉还具有抗氧化作用,冠心病患者连续服用1个月后,可使血清过氧化脂质明显降低。中老年人服用珍珠层粉2个月后,记忆力和运动能力有所改善,细胞免疫功能有所提高。
蒺藜:性微温,味辛、苦,有小毒。归肝经。平肝解郁,活血祛风,明目,止痒。属平肝息风药下属分类的平肝息风药。用治头痛眩晕,胸胁胀痛,乳闭乳痈,目赤翳障,风疹瘙痒。临床上常配草决明、青葙子等治头痛、头晕等症。此外,还可用于肝气郁结、胸胁不舒等。可配菊花、地肤子、苦参等治皮肤瘙痒风疹,去刺研末为丸,治疗白癜风等病。果实和叶含刺蒺藜苷(tribuloside)、紫云英苷(astragalin)、山柰素-3-芸香糖苷(kaempferol-3-rutinoside)及山柰素;并含生物碱哈尔满碱(harmane)和哈尔明碱(harmine),以及少量挥发油和油脂。药理实验表明蒺藜水提取部分有轻度降压作用,生物碱部分有轻度利尿作用,并对在体蛙心呈抑制作用。此外,蒺藜水提取部分有抗变态反应,对2,4-二硝基氯苯引起的小鼠接触性皮炎有抑制作用。
明党参:性微寒,味甘、微苦。归肺经、脾经、肝经。润肺化痰、养阴和胃、平肝、解毒。属平肝息风药下属分类的平抑肝阳药。用治风热咳嗽、痰黄黏稠、口干咽痛、疔毒疮疡、红肿热痛、脾胃不和之呕吐、湿热带下等。含有挥发油,挥发油中含50多种化合物,已鉴定出10种成分,其中含量最高的6,9一十八碳二炔酸甲酯被认为是润肺化痰的有效成分;还含有20多种氨基酸和18种微量元素;L-天门冬酰胺可能是其镇咳平喘的有效成分。可用薄层扫描法测定明党参中L-天门冬酰胺的含量。药理研究表明,本品有祛痰、止咳、平喘的作用,具有调节血脂、抗氧化、抗应激的作用;对正常小鼠的小肠蠕动有促进作用。
紫贝齿:性平,味咸。归肝经。镇惊安神、平肝明目。属平肝息风药下属分类的平抑肝阳药。用治小儿高热抽搐、头晕目眩、惊悸心烦、失眠多梦、目赤肿痛、热毒目翳。
石决明:性寒,味咸。归肝经。平肝潜阳,清肝明目。属平肝息风药下属分类的平抑肝阳药。用治头痛眩晕,目赤翳障,视物昏花,青盲雀目。主含碳酸钙,并含壳角质、胆壳素和多种微量元素。实验表明,其提取液对金黄葡萄球菌、大肠杆菌、绿脓杆菌有较强抑制作用;其贝壳内层水解液可显著降低四氯化碳急性中毒小白鼠谷丙转氨酶。其酸性提取液对家兔体内、外均具有显著的抗凝作用。其贝壳提取液对小白鼠常压下缺氨实验有明显的耐氧作用;还可使离体小鼠肺的灌流量增加,扩张气管、支气管的平滑肌(扩张率17%)。水煎醇沉提取液对实验小鼠具有免疫抑制作用。
罗布麻叶:性凉,味甘、苦。归肝经。平肝安神、清热利水。属平肝息风药下属分类的平抑肝阳药。用治肝阳眩晕、心悸失眠、浮肿尿少、高血压、神经衰弱、肾炎浮肿。含黄酮类化合物,含量达2%。另含儿茶素、蒽醌、谷氨酸、丙氨酸、缬氨酸、氯化钾等,预试尚含甾体化合物。药理试验表明,水煎剂有降压作用,同时还具有止咳、祛痰、利尿等作用。
全蝎:性平,味辛,有毒。归肝经。息风镇痉、攻毒散结、通络止痛。属平肝息风药下属分类的息风止痉药。用于小儿惊风、抽搐痉挛、中风口歪、半身不遂、破伤风、风湿顽痹、偏正头痛、疮疡、瘰疬。
牛黄:甘,凉。归心经、肝经。清心,豁痰,开窍,凉肝,熄风,解毒。用于热病神昏,中风痰迷,惊痫抽搐,癫痫发狂,咽喉肿痛,口舌生疮,痈肿疔疮。钩藤:性凉,味甘。归肝经、心包经。清热平肝、息风定惊。属平肝息风药下属分类的息风止痉药。用治头痛眩晕、惊厥抽搐、妊娠子痫及高血压症。含钩藤碱、异钩藤碱、毛钩藤碱、去氢毛钩藤碱等生物碱。含有喜果苷、金丝桃苷、三叶豆苷。药理实验表明,具抗惊厥、镇静及降压的作用。
首乌藤:性平,味甘。归心经、肝经。养血安神、祛风通络。属安神药下属分类的养心安神药。用治失眠多梦、血虚身痛、风湿痹痛,治疗精神分裂症具一定疗效。煎剂灌服能显著降低高血脂大鼠的血清胆固醇含量对戊巴比妥钠阈下睡眠时间有协同作用,能加强小鼠睡眠。所含的大黄素对离体、在体肠管小剂量肌张力增加,大剂量呈抑制作用。此外,还有抗菌镇咳、抗癌作用。
缬草:性平,味苦,微甘。归心经、肝经。具有宁心安神的功效。属安神药下属分类的养心安神药。临床多用于治疗神经衰弱、失眠和癔病及其情绪激动。现代药理实验结果证实了缬草具有镇静安定及降温的作用。此外还证实缬草具有短暂的降压作用和保肝作用。
藏菖蒲:性温,味苦、辛。无归经。温胃,消炎止痛。属消食药。治疗痰热惊厥等。现代药理试验结果表明,藏菖蒲具有安神镇静、抗惊厥和降温等作用。此外,尚有解平滑肌痉挛等药理作用。
鸡内金:性平,味甘。归脾经、胃经、小肠经、膀胱经。健胃消食、涩精止遗。属消食药。治食积不消、呕吐泻痢、小儿疳积、遗尿、遗精。
啤酒花:性微凉,味苦;无毒。归肝经、胃经。健胃消食、利尿安神。属消食药。治疗消化不良、腹胀、浮肿、膀胱炎、肺结核、失眠。对致病性、非致病性真菌及放线菌抑制效力极弱;蛇麻酮、氢草酮具有镇静作用;树脂中的β-酸具有较强的雌性激素样作用;酿造啤酒时加入本品,不仅由于其挥发油具有香味,而且有防腐作用;乙醇提取物对离体兔空肠、豚鼠十二指肠、大鼠子宫平滑肌有强大的解痉作用,并能拮抗乙酰胆碱、氯化钡的致痉作用。毒性:与本品接触者易发生皮炎,主要由鲜花粉所致;蛇麻酮能引起胃肠道反应,如食欲不振、烧灼感、恶心、腹痛、呕吐、腹泻等;动物争性毒性实验,于死亡前有兴奋及抽搐现象,死于呼吸困难,肝肾肺有明显的充血或出血现象。
梅花:性平,味微酸。归肝经、胃经、肺经。开郁和中、化痰、解毒。属理气药。用治肝胃气滞所致胁肋胀痛、脘腹痞痛、暖气纳呆、梅核气等,含挥发油,主要有苯甲酸醛、苯甲醇、4-松油烯醇、棕榈酸、苯甲酸和异丁香油酚等,还含有黄酮类化合物芦丁、槲皮素、绿原酸等。
香附:性平,味辛、微苦、微甘。归肝经、脾经、三焦经。行气解郁、调经止痛。属理气药。用治肝胃不和、气郁不舒、胸腹胁肋胀痛、痰饮痞满、月经不调、崩漏带下等。挥发油约1%,油中含有多种倍半萜及其氧化物,还含有少量单萜化合物和考布松等。挥发油及醇提取物对大鼠有显著的镇痛和解热作用。本品还有松弛平滑肌和雌激素样作用,有抗炎、保肝利胆等药理作用。
沉香:味辛、苦,性微温。归肾经、脾经、胃经。行气止痛、温中止呕、纳气平喘。属理气药,临床用治寒性胃痛、老年性肠梗阻、便秘、哮喘等。水煎液对离体豚鼠回肠的自主收缩有抑制作用,并能对抗组胺、乙酰胆碱引起的痉挛性收缩。醇提物能促进离体豚鼠气管抗组胺作用,从而发挥止喘效果。此外,具解痉、镇静、镇痛、降压、抗菌的作用。用治胸腹胀闷疼痛、胃寒呕吐呃逆、肾虚气逆喘急。含挥发油及树脂。挥发油中主要成分为白木香酸、白木香醛、α-沉香呋喃、β-沉香呋喃;受曲霉菌感染的沉香挥发油中含沉香螺萜醇、沉香螺萜醛等。
玫瑰花:性温,味甘、微苦。归肝、脾经。行气解郁、和血止痛。属理气药。用治肝胃不和、胁痛脘闷、胃脘胀痛;月经不调、经前乳房胀痛;跌打损伤、瘀肿疼痛等。含挥发油,油中主要成分有β-香茅醇等,此外,还含庚醛、香茅醛等。本品有抗病毒、抗肿瘤、促进大鼠胆汁分泌等作用;还有维生素P样作用;并可解除小鼠口服酒石酸锑钾的毒性反应,同时可使酒石酸锑钾抗血吸虫作用消失。
荔枝核:行气散结、祛寒止痛。属理气药。性温,味甘、微苦。归肝经、肾经。含脂肪酸、氨基酸、聚合花素类等成分。具有降血糖、抑制乙肝抗原等作用。
本发明以健胃消食、行气解郁、养心安神为治则,多种药材组合协同,主要用于清热平肝、息风定惊,大补元气,补脾益肺,生津安神,对精神疾病患者有显著的治疗作用。
临床观察:
(1)临床资料
本发明人于2007年至今,对296例精神疾病患者患者进行临床观察治疗,年龄28~45岁。
(2)治疗方法
口服,一日三次,每次2~5g,饭后服用。根据患者病情轻重计算治疗时间,轻度患者服用15~20天左右,重病患者连服20~60天即可痊愈。
(3)疗效判定标准
治愈:症状消失,实验室检查正常。
显效:症状明显减轻,偶有复发,但继续服药后症状很快改善。
有效:症状减轻,精神好转,但容易其它诱因而复发或加重。
无效:临床症状无明显好转或加重。
(4)临床结果
临床治愈236例(79.73%),显效37例(12.50%),有效19例(6.42%),无效4例(1.35%),总有效率为98.65%。
本发明配制简单,吸收效果好,药效持续时间长,疗效显著,无副作用,安全性高,生产成本低,有利于病患及时减轻病状。
(四)具体实施方式
实施例1:
取安息香0.6克,石菖蒲,3克,苏合香0.3克,冰片0.03克,麝香0.03克,蝉花3克,珍珠母10克,蒺藜6克,明党参3克,紫贝齿10克,石决明3,罗布麻叶6~克,全蝎2.5克,牛黄0.15克,钩藤3克,首乌藤9克,缬草3克,藏菖蒲3克,鸡内金3克,啤酒花1.5克,梅花2.5克,香附6克,沉香1.5克,玫瑰花3克,荔枝核4.5克,将上述原料清洗干净,打粉混合,制成散剂或丸剂。
用法用量:口服,一日三次,每次2~5g,饭后服用。
实施例2:
取安息香1.5克,石菖蒲,6克,苏合香1克,冰片0.1克,麝香0.1克,蝉花6克,珍珠母25克,蒺藜9克,明党参9克,紫贝齿15克,石决明15克,罗布麻叶12克,全蝎4.5克,牛黄0.35克,钩藤12克,首乌藤15克,缬草6克,藏菖蒲6克,鸡内金9克,啤酒花5克,梅花4.5克,香附9克,沉香4.5克,玫瑰花6克,荔枝核9克,将上述原料清洗干净,打粉混合,制成散剂或丸剂。
用法用量:口服,一日三次,每次2~5g,饭后服用。
实施例3:
取安息香1克,石菖蒲,4克,苏合香0.5克,冰片0.06克,麝香0.05克,蝉花4克,珍珠母16克,蒺藜7克,明党参7克,紫贝齿13克,石决明9克,罗布麻叶8克,全蝎3.5克,牛黄0.25克,钩藤7克,首乌藤12克,缬草4.5克,藏菖蒲4克,鸡内金6克,啤酒花3克,梅花3克,香附7克,沉香2.5克,玫瑰花4克,荔枝核6克,将上述原料清洗干净,打粉混合,制成散剂或丸剂。
用法用量:口服,一日三次,每次2~5g,饭后服用。
Claims (3)
1.一种精神疾病患者用的护理型中药组合,其特征为,由以下重量份数的原料制成:安息香0.6~1.5克,石菖蒲,3~6克,苏合香0.3~1克,冰片0.03~0.1克,麝香0.03~0.1克,蝉花3~6克,珍珠母10~25克,蒺藜6~9克,明党参3~9克,紫贝齿10~15克,石决明3~15克,罗布麻叶6~12克,全蝎2.5~4.5克,牛黄0.15~0.35克,钩藤3~12克,首乌藤9~15克,缬草3~6克,藏菖蒲3~6克,鸡内金3~9克,啤酒花1.5~5克,梅花2.5~4.5克,香附6~9克,沉香1.5~4.5克,玫瑰花3~6克,荔枝核4.5~9克。
2.根据权利要求1所述的一种精神疾病患者用的护理型中药组合,其特征为,由以下重量份数的原料制成:安息香0.6克,石菖蒲,3克,苏合香0.3克,冰片0.03克,麝香0.03克,蝉花3克,珍珠母10克,蒺藜6克,明党参3克,紫贝齿10克,石决明3,罗布麻叶6~克,全蝎2.5克,牛黄0.15克,钩藤3克,首乌藤9克,缬草3克,藏菖蒲3克,鸡内金3克,啤酒花1.5克,梅花2.5克,香附6克,沉香1.5克,玫瑰花3克,荔枝核4.5克。
3.根据权利要求1或2所述的一种精神疾病患者用的护理型中药组合,其特征在于:所述中药为散剂或丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510791496.3A CN105232865A (zh) | 2015-11-18 | 2015-11-18 | 一种精神疾病患者用的护理型中药组合 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510791496.3A CN105232865A (zh) | 2015-11-18 | 2015-11-18 | 一种精神疾病患者用的护理型中药组合 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105232865A true CN105232865A (zh) | 2016-01-13 |
Family
ID=55030859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510791496.3A Pending CN105232865A (zh) | 2015-11-18 | 2015-11-18 | 一种精神疾病患者用的护理型中药组合 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105232865A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396494A (zh) * | 2008-10-25 | 2009-04-01 | 宁甲保 | 治疗精神分裂症的中药制剂和制备方法及恢复药物 |
CN103127486A (zh) * | 2013-02-26 | 2013-06-05 | 徐芳 | 一种治疗精神分裂症伴严重失眠的中药组合物及其制备方法 |
-
2015
- 2015-11-18 CN CN201510791496.3A patent/CN105232865A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396494A (zh) * | 2008-10-25 | 2009-04-01 | 宁甲保 | 治疗精神分裂症的中药制剂和制备方法及恢复药物 |
CN103127486A (zh) * | 2013-02-26 | 2013-06-05 | 徐芳 | 一种治疗精神分裂症伴严重失眠的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
李禄斌,林立富: "中药浓缩剂治疗精神分裂症临床观察", 《新中医》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
CN103860978B (zh) | 一种治疗褥疮的中药制剂及其制备方法 | |
CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN105213941A (zh) | 一种用于治疗小儿腹泻的中药组合物及其制备方法 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN103182064A (zh) | 一种治疗风寒咳嗽的药物及其制备方法 | |
CN104474104A (zh) | 一种防治鸡传染性鼻炎的中药组合物及其制备方法 | |
CN103656048B (zh) | 用于治疗奶牛乳房炎的药物及其制备方法 | |
CN106389881A (zh) | 一种活血散瘀膏 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
CN103169863B (zh) | 一种治疗便秘的药物及其制备方法 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN105343346A (zh) | 一种治疗外阴瘙痒的中药片剂及其制备方法 | |
CN104225569A (zh) | 一种治疗慢性肠炎的中药组合物 | |
CN103705639A (zh) | 一种治疗脑积水的中药制剂 | |
CN105232865A (zh) | 一种精神疾病患者用的护理型中药组合 | |
CN107137689A (zh) | 一种治疗更年期综合征的中药组合物 | |
CN105106590A (zh) | 一种用于治疗过敏性鼻炎的药物 | |
CN103948904A (zh) | 用于治疗风痰阻闭型眩晕性癫痫病的药物及其制备方法 | |
CN104740403A (zh) | 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |